Rapid Discovery and Identification of a Tissue-specific Tumor Biomarker from 39 Human Cancer Cell Lines Using the SELDI ProteinChip Platform
Overview
Authors
Affiliations
Useful biomarkers are needed for early detection of cancers. To demonstrate the potential diagnostic usefulness of a new proteomic technology, we performed Expression Difference Mapping analysis on 39 cancer cell lines from 9 different tissues using ProteinChip technology. A protein biomarker candidate of 12kDa was found in colon cancer cells. We then optimized the purification conditions for this biomarker by utilizing Retentate Chromatography mass spectrometry (RC-MS). The optimized purification conditions developed "on-chip" were directly transferred to conventional chromatography to purify the biomarker, which was identified as prothymosin-alpha by ProteinChip time-of-flight mass spectrometry (TOF MS) and ProteinChip-Tandem MS systems. The relative expression level of prothymosin-alpha between colon cancer cells and normal colon mucosal cells was evaluated on the same ProteinChip platform. Prothymosin-alpha expression in colon cancer cells was clearly higher than in normal colon cells. These results indicate that prothymosin-alpha could be a potential biomarker for colon cancer, and that the ProteinChip platform could perform the whole process of biomarker discovery from screening to evaluation of the identified marker.
Proteomic study of benign and malignant pleural effusion.
Li H, Tang Z, Zhu H, Ge H, Cui S, Jiang W J Cancer Res Clin Oncol. 2016; 142(6):1191-200.
PMID: 26945985 DOI: 10.1007/s00432-016-2130-7.
Discrimination of normal and esophageal cancer plasma proteomes by MALDI-TOF mass spectrometry.
Schwacke J, Millar T, Hammond C, Saha A, Hoffman B, Romagnuolo J Dig Dis Sci. 2015; 60(6):1645-54.
PMID: 25577268 DOI: 10.1007/s10620-014-3513-8.
Zhang M, Cui F, Lu S, Lu H, Jiang T, Chen J Int J Clin Exp Pathol. 2014; 7(8):4867-76.
PMID: 25197357 PMC: 4152047.
Kim H, Kang D, Moon M, Kim H Yonsei Med J. 2014; 55(4):1014-27.
PMID: 24954332 PMC: 4075362. DOI: 10.3349/ymj.2014.55.4.1014.
Overexpression of prothymosin alpha predicts poor disease outcome in head and neck cancer.
Tripathi S, Matta A, Kaur J, Grigull J, Chauhan S, Thakar A PLoS One. 2011; 6(5):e19213.
PMID: 21573209 PMC: 3088661. DOI: 10.1371/journal.pone.0019213.